Novo provides update on the denecimig Biologics License Application (BLA) in the US
Denecimig also received a positive European regulatory committee opinion on 17 September, with marketing approval still pending.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novo Nordisk (NVO) announced that the FDA review of denecimig for haemophilia A remains ongoing because of manufacturing facility remediation. The application covers adults and children, with or without inhibitors. A decision had been anticipated in the third quarter of 2026, but the FDA has not communicated a new timeline.
The FDA has identified no deficiencies in the submitted clinical efficacy or safety data. Novo is addressing outstanding manufacturing requirements; the site feedback does not affect other marketed Novo products. Novo says the extended review does not affect its 2026 financial outlook and aims to launch denecimig in the US in the first half of 2027, pending a regulatory decision.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointSubmitted clinical efficacy and safety data have no FDA-identified deficiencies.
- Minor pointNovo's 2026 financial outlook is unchanged by the extended FDA review.
- Minor pointManufacturing site feedback has no impact on other marketed Novo products.
- Minor point. Forward-looking: it has not happened yet and may not happen.Novo aims for a US launch in the first half of 2027, pending a regulatory decision.
- Minor pointDenecimig received a positive CHMP opinion from the European regulatory committee on 17 September.
Negative
- Moderate pointFDA review extends beyond the anticipated third-quarter 2026 decision, with no new timeline communicated.
- Minor pointManufacturing facility remediation remains ongoing, with outstanding FDA requirements being addressed.
- Minor pointDenecimig's European marketing approval remains pending; other regulatory authorities are also reviewing it.
Key Figures
- Anticipated FDA decision
- Q3 2026
- Original expected decision timing; review has since been extended
- Planned US launch
- First half of 2027
- Novo's stated aim, pending regulatory decision
Key Terms
marketing authorisation application regulatory
chmp opinion regulatory
bispecific antibody medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for regulatory action on the BLA
- The FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency's review. The FDA has not identified any deficiencies related to the clinical efficacy or safety data submitted in the denecimig BLA
- Novo is actively working with the FDA, addressing the Agency's requests for remediations related to the manufacturing facility. The extended FDA review time for the denecimig BLA has no impact on Novo's financial outlook for 2026 and pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027
Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
Novo submitted a BLA for denecimig for the treatment of haemophilia A in adult and paediatric patients to the US FDA for review in September 2025, with an anticipated regulatory decision in the third quarter of 2026. Following this submission, the FDA performed a pre-license inspection of the manufacturing site and provided feedback. Today, the FDA has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency's review.
“Haemophilia A patients should expect more from their standard of care,” said Mike Doustdar, president and CEO of Novo. “As Novo prepares to bring denecimig to market, our ambition is to help make better care something they can count on. Novo is already in the process of addressing the FDA's requests as efficiently as possible and continuing to work closely with the Agency toward bringing denecimig to patients in the US.”
The Agency has not identified deficiencies related to the clinical efficacy or safety data of denecimig demonstrated in the FRONTIER clinical trial programme. Novo is continuing implementation of the facility remediation activities in response to the FDA's feedback and is working closely with the Agency to address the outstanding requirements. The feedback on the manufacturing site does not impact other marketed Novo products.
The additional FDA review time does not have an impact on Novo's financial outlook for 2026. Pending regulatory decision, Novo aims to launch denecimig in the US in the first half of 2027.
About the FRONTIER trials
The FRONTIER clinical programme includes FRONTIER1-5 and investigates denecimig as a prophylactic treatment to prevent bleeding episodes across paediatric and adult populations with haemophilia A, with or without inhibitors.
FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the denecimig Marketing Authorisation Application (MAA) submission. FRONTIER2 evaluated denecimig treatment once every month and once every week in adults and adolescents 12 years of age and older; FRONTIER3 evaluated denecimig treatment once every month and once every week in children below the age of 12; FRONTIER4 was an open-label extension trial evaluating the efficacy of denecimig once every two weeks (Q2W) as well as investigating the long-term safety of denecimig across all dosing regimens (once every month, once every two weeks, and once every week) in subjects with haemophilia A, with or without inhibitors.
About denecimig
Denecimig is a FVIIIa mimetic bispecific antibody designed with the aim to deliver once monthly, every two weeks and weekly prophylaxis for people living with haemophilia A, with or without inhibitors. Denecimig, which is administered under the skin, ‘mimics’ the role of FVIIIa by bridging factor IXa and factor X. This action mimics the cofactor function of FVIIIa, which helps restore the body’s thrombin generation capacity, helping blood to clot. On 17 September, denecimig received a positive CHMP opinion and is currently pending marketing approval from the EMA and under review by other regulatory authorities.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.
Publication of inside information pursuant to Market Abuse Regulation, Article 17.
Contacts for further information
| Novo Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Novo Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Max Ung +45 3077 6414 mxun@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com | Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com |
Company announcement No 59 / 2026
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why is Novo Nordisk's denecimig FDA review delayed?
The FDA review is extended because manufacturing facility remediation activities remain ongoing. Novo is implementing remediation and addressing outstanding requirements. The FDA has not identified deficiencies in the submitted clinical efficacy or safety data and has not communicated a new regulatory action timeline.
When does Novo Nordisk aim to launch denecimig in the US?
Novo aims to launch denecimig in the US in the first half of 2027, pending a regulatory decision. The FDA review remains ongoing, so this is a company target rather than a confirmed launch date.